ERCC4 and neoplasm: Finally, we used the HCT116 and SW620 tumor-bearing mice to analyze whether the XPF–ERCC1 blocker can increase the therapeutic effect of 5-FU, OXA, 5-FU-based CRT, or OXA-based CRT in vivo.